TScan Q2 net loss $37M, cash ~$218M funds ops into Q1 2027; heme/solid tumor milestones on track

TScan Therapeutics, Inc.

2025-Q2 EPS reported -$0.55 revenue$5,247,000

Q2 2025 revenue $3.1M (vs $0.5M YoY) from Amgen collaboration; R&D spend $32.6M.
Net loss $37M vs $31.7M in Q2 2024; cash+equivalents+securities $218M (excl. $5M restricted).
Expects to dose first solid tumor patients with multiplex TCR-T in Q3 2025; initial safety/response data in Q1 2026.
Plans to initiate registrational trial for TSC-101 in H2 2025 and file IND for TSC-102-A0301 in H2 2025.
ALL OHA Phase 1 two-year relapse data on TSC-101 to be presented by end of 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.